查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847953

抗苗勒氏管激素檢測市場：按產品、組件、應用和最終用戶分類 - 全球預測（2025-2032 年）

Anti-Mullerian Hormone Test Market by Product, Component, Applications, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗苗勒氏管激素 (AMH) 檢測市場將成長至 7.4442 億美元，複合年成長率為 11.78%。

主要市場統計數據
基準年 2024 3.0541億美元
預計年份：2025年 3.4021億美元
預測年份：2032年 7.4442億美元
複合年成長率 (%) 11.78%

透過綜合考慮臨床效用、獲取途徑和技術成熟度，建構現代抗苗勒氏管激素檢測的格局。

本執行摘要全面回顧了抗苗勒氏管激素（AMH）檢測，並整合了臨床發展、技術創新和相關人員的期望。分析首先將AMH檢測置於現代生殖醫學的背景下，指出診斷準確性和以患者為中心的便利性正在再形成臨床診療流程。診斷實驗室、生育診所、醫院和研究機構越來越依賴AMH作為生育治療方案製定、治療分層和長期卵巢健康監測的關鍵生物標記。在此背景下，就地檢驗和自我測試劑套件作為補充性的便捷檢測方式應運而生，以滿足對更快檢測週期和分散式檢測的需求。

儀器、試劑和檢測設計的技術成熟正在提高分析靈敏度和操作效率，使臨床醫生更有信心地根據結果採取行動。同時，支付方觀點的轉變和監管審查正在影響著檢測方法的應用模式和採購標準。這些應用情況為後續章節提供了依據，闡明了關鍵概念，明確了主要相關人員，並概述了構成當代AMH檢測格局的診斷、商業和監管因素。這為解讀報告中的市場細分洞察、區域動態和策略建議提供了必要的背景。

確定將重塑AMH診斷在各個醫療管道的交付和應用方式的臨床、技術和商業性促進因素。

隨著臨床、技術和商業性因素的共同作用，AMH檢測領域正在經歷變革時期，重塑生殖診斷的提供和應用方式。在臨床上，對個人化生育治療方案和早期療育的日益重視，提升了AMH作為縱向生物標記的地位，促使醫療機構將系列檢測整合到診療流程中，而非依賴單次評估。這種向縱向監測的轉變，刺激了對能夠在不同檢測環境下提供一致且可重複結果的檢測方法的需求，從而推動了標準化和跨平台協調的進程。

在技​​術層面，桌上型儀器和可攜式分析儀的普及正在使實驗室工作流程分散化，而試劑和套件（包括客製化和標準化檢測）的創新則在保證分析性能相當的前提下，實現了更快的周轉速度。同時，即時檢測和自測試劑套件的興起，正在將檢測範圍擴展到傳統臨床環境之外，並支援遠端醫療模式和患者自主管理。從商業性角度來看，競爭優勢越來越依賴綜合提案，包括分析準確性、易用性和整合式數位報告，以支援臨床醫生的決策和患者的參與。

監管預期也在同步演變，監管機構越來越重視檢測方法的檢驗、臨床相關性以及真實世界表現的證據。這種轉變正在加速診斷試劑生產商、臨床網路和數位醫療服務提供者之間的夥伴關係，並鼓勵生產商優先考慮互通性、品管系統和上市後監測，以維持臨床信心和產品應用。

評估近期關稅政策變化如何重塑AMH診斷價值鏈的供應鏈策略、採購行為和營運韌性。

2025年的關稅調整和貿易政策變化為支持AMH檢測所需診斷設備、試劑和耗材的全球供應鏈帶來了更多複雜性。進口關稅的上漲導致先進的桌上型儀器、攜帶式分析儀和試劑組的到岸成本增加，給診斷實驗室、生育診所和醫院的採購預算帶來了壓力。為此，一些製造商正在重新審視籌資策略，加快對替代供應商的資格認證，並探索關鍵零件的近岸外包和在岸外包方案，以確保供應連續性不受關稅波動的影響。

依賴跨境供應專業生物試劑和檢測組件的試劑盒和套件生產商也感受到了關稅帶來的累積成本壓力。當關稅增加投入成本時，除非企業透過流程最佳化、合約重新談判和策略性定價調整來適應，否則利潤空間將被壓縮。如果生產或標籤變更需要在目標市場進行新的備案和驗證，監管時間表會進一步加劇這些應對措施的複雜性。

從營運角度來看，終端用戶面臨設備購置和試劑成本上漲的困境，可能會推遲設備升級，或優先選擇單次檢測營運成本較低的高通量檢測方式。同時，商業策略可能會更加注重配套服務協議、耗材訂閱模式和本地化技術支持，以降低用戶感知到的風險。關稅政策的變化促使價值鏈上的相關人員提高供應鏈透明度、實現採購多元化並加強應急計畫，以確保生殖健康所需的診斷能力得以持續。

了解產品模式、組件架構、臨床應用和最終用戶需求如何交織，共同決定AMH檢測的機會和應用前景。

細分市場層面的動態揭示了不同的需求、營運要求和創新管道，這些因素共同指導產品設計、打入市場策略和臨床應用。依產品類型分類，市場格局可分為就地檢驗和自測試劑套件，二者分別針對不同的應用場景。照護現場平台滿足需要快速獲得臨床醫生解讀結果的臨床環境需求，而自測試劑套件滿足消費者自主檢測和遠端監測的需求。按組件分類，儀器和試劑/試劑套件構成了技術核心，其中儀器涵蓋台式和可攜式分析儀，兼顧了通量和分散性；試劑/試劑套件包括專為特定臨床檢驗而設計的客製化檢測方法和針對廣泛互通性最佳化的標準檢測方法。

應用細分透過將應用分為卵巢儲備評估、多卵巢症候群診斷和卵巢早衰預測三大類，進一步明確了臨床優先事項。例如，卵巢儲備評估將推動對具有可靠性和縱向可比性的檢測法的需求，而多囊性卵巢症候群診斷和卵巢早衰預測可能需要整合其他荷爾蒙標記和臨床演算法。從最終用戶來看，診斷實驗室、生育診所、醫院和研究機構的採購動機和工作流程限制各不相同。診斷實驗室優先考慮標準化和高通量，生育診所優先考慮臨床決策支援和患者諮詢，醫院需要與更廣泛的實驗室資訊系統整合，而研究機構則優先考慮檢測方法開發和檢驗的靈活性。

綜上所述，這些細分領域突顯了技術創新、監管證據和商業模式必須如何協調一致才能實現臨床價值。製造商和服務供應商若能根據產品類型、組件配置、應用和最終用戶環境的細微差別來客製化產品，將更有利於展現其臨床效用和營運契合度。

檢驗了決定全球主要市場AMH檢測普及程度的區域需求促進因素、法律規範和基礎設施現狀。

區域動態揭示了不同的需求促進因素、法規環境和基礎設施考量，這些因素共同塑造了全部區域的採納模式。在美洲，重點在於與現有生育管道的整合、報銷談判以及門診照護現場平台的應用，這裡的技術創新通常側重於可擴展性，以支持高容量的生育項目和臨床醫生的分析。同時，歐洲、中東和非洲的監管和臨床環境則呈現出異質性，跨境協調努力、不同的報銷模式以及部分市場私人生育服務行業的擴張，都對產品參與策略和技術支援的本地化產生了影響。

亞太地區正迅速採用分散式檢查方法，這主要得益於私部門對生育服務的大力投資以及消費者對診斷解決方案日益成長的需求。該地區多元化的管理體制和生產能力也為在地化生產夥伴關係和協作檢驗研究創造了機會。由於各地區在實驗室基礎設施、數位醫療整合以及支付方參與度方面存在差異，因此需要獨特的價值提案，以協調全球技術標準與本地臨床工作流程和採購實踐。因此，策略性參與企業將結合強力的臨床證據和靈活的商業化模式，以應對區域差異，同時確保產品完整性和合規性。

揭示當今AMH診斷領導者的競爭重點、合作策略以及產品和服務整合方法。

AMH檢測領域的競爭格局由成熟的診斷公司、專注於生殖健康的公司以及致力於去中心化和提升檢測性能的敏捷創新者組成。主要企業正投資於跨平台相容性、提高分析準確性以及將檢測結果與臨床決策支援工具連接的整合彙報。與臨床網路和學術中心的夥伴關係日益增多，旨在產生增強臨床效用價值所需的真實世界證據；同時，與數位醫療供應商的策略合作也有助於提升病人參與和遠端監測能力。

在組件層面，儀器製造商正專注於支援桌上型和可攜式部署的模組化設計，而試劑和試劑套件開發商則優先考慮檢測的穩健性和批次間一致性。提供客製化檢測的公司可以透過客製化驗證研究和與大型生育中心的共同開發契約來脫穎而出。同時，提供標準檢測的公司則優先考慮易於實施和與各種儀器平台的互通性。服務模式也在不斷發展。製造商正在擴展售後服務支援、培訓計劃和基本契約，以減少臨床應用過程中的阻力。隨著醫療機構尋求值得信賴的合作夥伴以實現永續的診斷營運，那些兼具監管專業知識、供應鏈韌性和可擴展生產能力的公司很可能獲得競爭優勢。

診斷試劑生產商和臨床領導者可採取切實可行的策略重點，以加速產品應用，同時增強供應鏈韌性和臨床信心。

產業領導者應採取切實可行的策略，平衡創新、可及性和營運韌性，以滿足不斷變化的臨床需求。首先，應優先考慮檢測方法的標準化和跨平台協調，以確保長期可比性並增強臨床醫生的信心。其次，應實現採購管道多元化，並考慮建立區域性生產夥伴關係，以降低關稅和供應鏈波動的影響。這些措施有助於提高供應的連續性，並縮短關鍵試劑和耗材的前置作業時間。

同步數位化至關重要。應將安全、以臨床醫生為導向的彙報整合到遠端醫療工作流程中，以支援遠距會診和長期病患管理。商業模式應不斷發展，包括配套服務協議、耗材訂閱和基於績效的契約，從而減少終端用戶的採購摩擦。此外，應與生育診所和學術機構建立合作研究夥伴關係，共同產生真實世界證據，並改善用於卵巢儲備評估和多囊性卵巢症候群（PCOS）診斷等應用的臨床演算法。最後，應投資於有針對性的監管策略和市場推廣計劃，以應對不同的區域性要求，同時保持產品品質和上市後監測，從而保障臨床信心和產品的長期應用。

概述了一種混合方法研究途徑，該方案結合了專家參與、文獻綜述和技術檢驗，以確保研究結果的可靠性和可操作性。

本綜述的研究採用了混合方法，結合了主要相關人員的參與和二手證據的綜合分析，以確保研究的深度和情境效度。主要資訊來源包括對臨床醫生、實驗室主任、生育專家和採購負責人進行結構化訪談，以了解營運重點、檢驗預期和採購行為。這些訪談為定性編碼提供了依據，從而揭示了與檢測性能要求、部署限制和最終用戶支援需求相關的反覆出現的主題。

二次分析納入了同儕審查文獻、監管指導文件和已發布的臨床實踐指南，以檢驗診斷概念並使分析標準與臨床相關性保持一致。我們審查了行業技術文件和產品規格，以評估儀器架構、檢測化學和互通性特性。我們透過貿易和監管公告評估了供應鍊和政策發展情況，並從公開的技術報告和臨床檢驗研究中獲取了儀器和試劑選項的比較評估。這些資訊來源的交叉驗證增強了結論的可靠性，並確保建議既反映了實際操作情況，也反映了臨床需求。

將臨床需求、技術能力和營運韌性聯繫起來，為AMH診斷的策略決策提供指導，並得出最終結論。

總之，抗苗勒氏管激素檢測領域正處於曲折點患者為中心的縱向診斷的臨床需求與實現去中心化和提升分析性能的技術能力相融合。價值鏈上的相關人員必須應對受關稅主導的供應鏈動態、各地區的不同要求以及不斷變化的臨床預期，這些因素共同決定了檢測的普及模式。只有那些投資於檢測標準化、供應鏈多元化和數位化整合的機構，才能在各個醫療環節提供可靠且便於臨床醫生使用的檢測結果，從而取得成功。

此外，尊重個別需求的細分策略至關重要，該策略應涵蓋照護現場和自測模式、設備和試劑架構、特定應用的分析標準以及多樣化的終端用戶工作流程。透過協調證據生成、商業化模式和營運彈性，企業可以更好地支持臨床決策，擴大生殖健康診斷的覆蓋範圍，並最終改善患者預後。未來發展需要製造商、臨床醫生和醫療系統之間持續合作，將技術進步轉化為可靠、可擴展的診斷解決方案。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 生育診所採用即時抗穆氏管荷爾蒙檢測平台的照護現場激增
  • 整合新一代定序和生物標記分析技術，可實現AMH檢測結果的個人化解讀。
  • 由於生育年齡延遲以及女性對懷孕的認知提高，對AMH檢測的需求正在增加。
  • 快速微流體AMH檢測技術的出現顯著減少了樣本用量和檢測週期。
  • 擴大報銷範圍的措施改善了患者獲得抗穆氏管荷爾蒙檢測服務的機會。
  • 與診斷公司和遠端醫療平台建立合作關係，以實現遠端AMH監測解決方案
  • 新型體外診斷AMH檢測方法核准，推動新興地區市場擴張
  • 開發包含AMH標誌物的多重免疫檢測盒，用於全面的生殖健康評估

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 依產品分類的抗苗勒氏管激素檢測市場

  • POC測試
  • 自檢套件

9. 依成分分類的抗苗勒氏管激素檢測市場

  • 裝置
    • 桌上型裝置
    • 可攜式分析儀
  • 試劑和套件
    • 客製化檢測
    • 標準檢測

第10章 依應用分類的抗苗勒氏管激素檢測市場

  • 卵巢儲備評估
  • 卵巢的診斷
  • 預測卵巢早衰

第11章 依最終用戶分類的抗苗勒氏管激素檢測市場

  • 診斷實驗室
  • 不孕不育診所
  • 醫院
  • 研究所

第12章 抗苗勒氏管激素檢測市場（依地區分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 依組別分類的抗苗勒氏管激素檢測市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國抗苗勒氏管激素檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbexa Limited
    • Ansh Labs LLC
    • Athenese-Dx
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • bioMerieux SA
    • BioVendor-Laboratorni Medicina AS
    • Chengdu VACURE BIoTechnology Co., Ltd.
    • CTK BIoTech, Inc.
    • Cusabio Technology LLC
    • Danaher Corporation
    • Eagle Biosciences, Inc.
    • Elabscience Bionovation Inc.
    • Epitope Diagnostics, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Fujirebio Europe NV by HU Group Holdings, Inc.
    • Goldsite Diagnostics Inc.
    • Healthy Human Labs Limited（Vitall）
    • Kamiya Biomedical Company
    • LifeSpan BioSciences, Inc.
    • London Gynaecology Limited
    • Meridian Bioscience, Inc.
    • Monobind Inc.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Tosoh Corporation
    • Vitrosens BIoTechnology Co., Ltd.
Product Code: MRR-BC3400CDF7AF

The Anti-Mullerian Hormone Test Market is projected to grow by USD 744.42 million at a CAGR of 11.78% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 305.41 million
Estimated Year [2025] USD 340.21 million
Forecast Year [2032] USD 744.42 million
CAGR (%) 11.78%

Framing the contemporary Anti-Mullerian Hormone testing landscape by synthesizing clinical utility, access modalities, and technological maturation

This executive summary introduces a comprehensive examination of Anti-Mullerian Hormone testing, synthesizing clinical evolution, technological innovation, and stakeholder expectations into a cohesive narrative. The analysis begins by situating AMH testing within contemporary reproductive medicine, where diagnostic precision and patient-centric access are reshaping clinical pathways. Diagnostic laboratories, fertility clinics, hospitals, and research institutes increasingly rely on AMH as a critical biomarker to inform fertility planning, treatment stratification, and long-term ovarian health monitoring. Against this backdrop, both point-of-care testing and self-check kits are emerging as complementary access modalities that address demand for faster decision cycles and decentralized testing.

Technological maturation in instruments, reagents, and assay design has improved analytic sensitivity and operational throughput, enabling clinicians to act on results with greater confidence. Meanwhile, evolving payer perspectives and regulatory scrutiny are influencing adoption patterns and procurement criteria. This introduction frames the subsequent chapters by clarifying key concepts, identifying primary stakeholders, and outlining the diagnostic, commercial, and regulatory forces that together define the contemporary AMH testing landscape. It provides the context necessary for interpreting segmentation insights, regional dynamics, and strategic recommendations contained in the report.

Identifying the convergent clinical, technological, and commercial drivers that are restructuring how AMH diagnostics are delivered and adopted across care pathways

The AMH testing landscape is undergoing transformative shifts driven by converging clinical, technological, and commercial forces that are rewriting how reproductive diagnostics are delivered and consumed. Clinically, greater emphasis on personalized fertility planning and earlier intervention is elevating the role of AMH as a longitudinal biomarker, prompting providers to integrate serial testing into care pathways rather than relying on single-point assessments. This shift toward longitudinal monitoring has stimulated demand for assays that deliver consistent, reproducible results across different testing environments, creating pressure for standardization and cross-platform harmonization.

On the technology front, the diffusion of benchtop devices and portable analyzers is decentralizing laboratory workflows, while reagents and kit innovations-both customized assays and standard assays-are enabling faster turnaround with comparable analytic performance. Simultaneously, the rise of POC testing and self-check kits is expanding access beyond traditional clinical settings, supporting telehealth models and patient-managed care. From a commercial perspective, competitive differentiation increasingly rests on combined propositions of analytic accuracy, ease of use, and integrated digital reporting that supports clinician decision-making and patient engagement.

Regulatory expectations are also evolving in parallel, with authorities focusing on assay validation, clinical correlation, and real-world performance evidence. These shifts are accelerating partnerships among diagnostic manufacturers, clinical networks, and digital health providers, and they are prompting manufacturers to prioritize interoperability, quality-control systems, and post-market surveillance to sustain clinical trust and adoption.

Assessing how recent tariff developments are reshaping supply chain strategies, procurement behavior, and operational resilience across the AMH diagnostic value chain

Tariff adjustments and trade policy changes in 2025 have introduced additional complexity into global supply chains that support diagnostic instruments, reagents, and consumables integral to AMH testing. Increased import duties can translate into higher landed costs for sophisticated benchtop devices, portable analyzers, and reagent kits, exerting pressure on procurement budgets in diagnostic laboratories, fertility clinics, and hospitals. In response, some manufacturers are reassessing sourcing strategies, accelerating qualification of alternative suppliers, and exploring nearshoring or onshoring options for critical components to shield supply continuity from tariff volatility.

The cumulative effect of tariff-driven cost pressures also extends to reagent and kit manufacturers who rely on cross-border supply of specialized biological reagents and assay components. Where tariffs elevate input costs, there is potential for margin compression unless firms adapt through process optimization, contract renegotiation, or strategic pricing adjustments. Regulatory timelines can further complicate these responses when modifications to manufacturing or labeling require renewed submissions or validations in target markets.

From an operational standpoint, end users facing higher equipment acquisition or reagent costs may defer upgrades or prioritize high-throughput testing modalities that offer lower per-test operational expense. In parallel, commercial strategies are likely to emphasize bundled service agreements, consumable subscription models, and localized technical support to mitigate perceived risk. Ultimately, tariff developments are prompting stakeholders across the value chain to increase supply chain transparency, diversify sourcing, and fortify contingency planning to preserve access to diagnostic capabilities critical to reproductive care.

Uncovering how product modalities, component architectures, clinical applications, and end-user needs interplay to define opportunity and adoption in AMH testing

Segment-level dynamics reveal differentiated demand, operational requirements, and innovation pathways that inform product design, go-to-market strategies, and clinical adoption. Based on product, the landscape distinguishes between point-of-care testing and self-check kits, each targeting distinct use cases: point-of-care platforms cater to clinical settings seeking rapid, clinician-interpreted results, while self-check kits address consumer empowerment and remote monitoring needs. Based on component, instruments and reagents & kits define the technical backbone, where instruments span benchtop devices and portable analyzers that balance throughput and decentralization, and reagents and kits include customized assays designed for niche clinical validation alongside standard assays optimized for broad interoperability.

Application segmentation further clarifies clinical priorities by grouping use into ovarian reserve assessment, polycystic ovary syndrome diagnosis, and premature ovarian failure prediction, each of which imposes unique analytical sensitivity and reporting requirements. For example, ovarian reserve assessment drives demand for assays with reliable longitudinal comparability, whereas PCOS diagnosis and premature ovarian failure prediction may require integration with additional hormonal markers and clinical algorithms. Based on end user, diagnostic laboratories, fertility clinics, hospitals, and research institutes present varied purchasing rationales and workflow constraints; diagnostic laboratories emphasize standardization and throughput, fertility clinics focus on clinical decision support and patient counseling, hospitals require integration with broader laboratory information systems, and research institutes prioritize flexibility for assay development and validation.

Collectively, these segmentation lenses expose where innovation, regulatory evidence, and commercial models must align to capture clinical value. Manufacturers and service providers that tailor offerings to the nuanced requirements across product types, component configurations, applications, and end-user contexts will be better positioned to demonstrate clinical utility and operational fit.

Examining distinct regional demand drivers, regulatory frameworks, and infrastructure realities that determine AMH testing adoption across leading global markets

Regional dynamics display distinct demand drivers, regulatory environments, and infrastructure considerations that shape adoption patterns across key geographies. In the Americas, the emphasis is on integration with established fertility care pathways, reimbursement negotiation, and the adoption of point-of-care platforms in outpatient settings; innovation here often focuses on scalability and clinician-facing analytics that support high-volume fertility programs. Meanwhile, the Europe, Middle East & Africa region presents a heterogeneous regulatory and clinical landscape where cross-border harmonization efforts, varying reimbursement models, and an expanding private fertility services sector in select markets influence product entry strategies and localization of technical support.

Asia-Pacific exhibits rapid adoption of decentralized testing modalities, buoyed by strong private-sector investment in fertility services and a growing appetite for consumer-facing diagnostic solutions. The region's diverse regulatory regimes and manufacturing capacity also create opportunities for localized production partnerships and collaborative validation studies. Across all regions, differences in laboratory infrastructure, digital health integration, and payer engagement necessitate tailored value propositions that reconcile global technical standards with local clinical workflows and procurement practices. Strategic entrants will therefore combine robust clinical evidence and flexible commercialization models to navigate regional nuances while maintaining product integrity and regulatory compliance.

Highlighting competitive priorities, collaboration strategies, and product-service integration approaches that differentiate leaders in AMH diagnostics today

Competitive dynamics in the AMH testing space reflect a mix of established diagnostics companies, specialized reproductive health firms, and agile innovators focused on decentralization and assay performance. Key players are investing in cross-platform compatibility, enhanced analytical precision, and integrated reporting that links laboratory results with clinical decision support tools. Partnerships with clinical networks and academic centers are increasingly used to generate the real-world evidence necessary to strengthen clinical utility claims, while strategic collaborations with digital health vendors facilitate patient engagement and remote monitoring capabilities.

At the component level, instrument manufacturers concentrate on modular designs that support both benchtop and portable deployments, whereas reagent and kit developers prioritize assay robustness and lot-to-lot consistency. Firms offering customized assays can differentiate through tailored validation studies and co-development agreements with large fertility centers, while providers of standard assays emphasize ease of adoption and interoperability with diverse instrument platforms. Service models are also evolving: manufacturers are expanding after-sales support, training programs, and performance-based contracting to reduce friction during clinical adoption. Companies that integrate regulatory expertise, supply chain resilience, and scalable manufacturing will hold competitive advantages as institutions seek reliable partners for sustained diagnostic operations.

Actionable strategic priorities for diagnostic manufacturers and clinical leaders to accelerate adoption while enhancing supply chain resilience and clinical trust

Industry leaders should pursue actionable strategies that balance innovation, access, and operational resilience to capitalize on evolving clinical needs. First, prioritize assay standardization and cross-platform harmonization to ensure longitudinal comparability and clinician confidence; investing in multicenter validation studies and alignment with laboratory quality frameworks will accelerate clinical acceptance. Next, diversify sourcing and consider regional manufacturing partnerships to mitigate tariff and supply chain volatility; such moves improve continuity of supply and can shorten lead times for critical reagents and consumables.

Concurrent digital enablement is essential: integrate secure, clinician-oriented reporting with telehealth workflows to support remote consultations and longitudinal patient management. Commercial models should evolve to include bundled service agreements, consumables subscriptions, and outcome-linked arrangements that reduce end-user procurement friction. Additionally, cultivate collaborative research alliances with fertility clinics and academic institutions to co-generate real-world evidence and refine clinical algorithms for applications such as ovarian reserve assessment and PCOS diagnosis. Finally, invest in targeted regulatory strategy and market access planning to navigate heterogeneous regional requirements while maintaining product quality and post-market surveillance, thereby protecting clinical trust and long-term adoption.

Outlining a mixed-methods research approach combining expert engagement, literature synthesis, and technical validation to ensure robust, actionable insights

The research underpinning this summary employed a mixed-methods approach combining primary stakeholder engagement and secondary evidence synthesis to ensure depth and contextual relevance. Primary inputs included structured interviews with clinicians, laboratory directors, fertility specialists, and procurement leaders to capture operational priorities, validation expectations, and purchasing behaviors. These discussions informed qualitative coding to surface recurring themes related to assay performance requirements, deployment constraints, and end-user support needs.

Secondary analysis incorporated peer-reviewed literature, regulatory guidance documents, and published clinical practice guidelines to validate diagnostic concepts and align analytical criteria with clinical relevance. Industry technical documentation and product specifications were reviewed to assess device architectures, assay chemistries, and interoperability features. Supply chain and policy developments were evaluated through trade and regulatory notices, while comparative assessments of instrumentation and reagent options were derived from publicly available technical reports and clinical validation studies. Triangulation across these sources strengthened the robustness of insights and ensured recommendations reflect both operational realities and clinical imperatives.

Concluding synthesis that connects clinical demand, technological capability, and operational resilience to guide strategic decisions in AMH diagnostics

In conclusion, the Anti-Mullerian Hormone testing landscape is at an inflection point where clinical demand for longitudinal, patient-centered diagnostics converges with technological capabilities that enable decentralization and improved analytic performance. Stakeholders across the value chain must navigate tariff-driven supply chain dynamics, heterogeneous regional requirements, and evolving clinical expectations that collectively determine adoption patterns. Success will favor organizations that invest in assay standardization, supply chain diversification, and digital integration to deliver reliable, clinician-usable results across care settings.

Moreover, segmentation-informed strategies that respect the distinct needs of point-of-care and self-check modalities, instrument and reagent architectures, application-specific analytical criteria, and diverse end-user workflows will be essential. By aligning evidence generation, commercialization models, and operational resilience, firms can better support clinical decision-making, expand access to reproductive health diagnostics, and ultimately improve patient outcomes. The path forward requires sustained collaboration among manufacturers, clinicians, and health systems to translate technical advances into dependable, scalable diagnostic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in adoption of point-of-care anti-Mullerian hormone testing platforms across fertility clinics
  • 5.2. Integration of next-generation sequencing and biomarker analytics for personalized AMH test interpretation
  • 5.3. Rising demand for AMH testing driven by delayed childbearing and increasing fertility awareness among women
  • 5.4. Emergence of microfluidics-based rapid AMH assays reducing sample volumes and turnaround times significantly
  • 5.5. Expansion of insurance reimbursement policies enhancing patient access to anti-Mullerian hormone testing services
  • 5.6. Partnerships between diagnostics companies and telehealth platforms enabling remote AMH monitoring solutions
  • 5.7. Regulatory approvals for novel in vitro diagnostic AMH assays fueling market expansion in emerging regions
  • 5.8. Development of multiplex immunoassay panels incorporating AMH markers for comprehensive reproductive health profiling

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Mullerian Hormone Test Market, by Product

  • 8.1. POC Testing
  • 8.2. Self-check Kits

9. Anti-Mullerian Hormone Test Market, by Component

  • 9.1. Instruments
    • 9.1.1. Benchtop Devices
    • 9.1.2. Portable Analyzers
  • 9.2. Reagents & Kits
    • 9.2.1. Customized Assays
    • 9.2.2. Standard Assays

10. Anti-Mullerian Hormone Test Market, by Applications

  • 10.1. Ovarian Reserve Assessment
  • 10.2. Polycystic Ovary Syndrome Diagnosis
  • 10.3. Premature Ovarian Failure Prediction

11. Anti-Mullerian Hormone Test Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Fertility Clinics
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Anti-Mullerian Hormone Test Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-Mullerian Hormone Test Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-Mullerian Hormone Test Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbexa Limited
    • 15.3.2. Ansh Labs LLC
    • 15.3.3. Athenese-Dx
    • 15.3.4. Bio-Rad Laboratories, Inc.
    • 15.3.5. Bio-Techne Corporation
    • 15.3.6. bioMerieux S.A.
    • 15.3.7. BioVendor - Laboratorni Medicina A.S.
    • 15.3.8. Chengdu VACURE Biotechnology Co., Ltd.
    • 15.3.9. CTK Biotech, Inc.
    • 15.3.10. Cusabio Technology LLC
    • 15.3.11. Danaher Corporation
    • 15.3.12. Eagle Biosciences, Inc.
    • 15.3.13. Elabscience Bionovation Inc.
    • 15.3.14. Epitope Diagnostics, Inc.
    • 15.3.15. F. Hoffmann-La Roche Ltd.
    • 15.3.16. Fujirebio Europe N.V. by H.U. Group Holdings, Inc.
    • 15.3.17. Goldsite Diagnostics Inc.
    • 15.3.18. Healthy Human Labs Limited (Vitall)
    • 15.3.19. Kamiya Biomedical Company
    • 15.3.20. LifeSpan BioSciences, Inc.
    • 15.3.21. London Gynaecology Limited
    • 15.3.22. Meridian Bioscience, Inc.
    • 15.3.23. Monobind Inc.
    • 15.3.24. Siemens Healthineers AG
    • 15.3.25. Thermo Fisher Scientific Inc.
    • 15.3.26. Tosoh Corporation
    • 15.3.27. Vitrosens Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTI-MULLERIAN HORMONE TEST MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTI-MULLERIAN HORMONE TEST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-MULLERIAN HORMONE TEST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 240. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 241. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 242. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 243. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 244. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 245. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 246. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 247. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 248. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 249. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 282. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 283. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 284. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 285. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 286. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 287. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 288. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 289. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 290. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 291. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 296. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 297. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 298. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 299. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 300. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 301. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 302. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 303. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 304. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 305. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-203